Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Death, recurrence in NSCLC not tied to opioid usage

29 Jul 2017
More than 33,000 have died in America from opioid overdose in 2015 alone.

Opioid usage is not associated with long-term outcomes such as death and risk of recurrence in non-small cell lung cancer (NSCLC) patients, a new study has found.

The study included 871 NSCLC patients stratified into quartiles according to opioid use. Only patients who underwent sleeve lobectomy, bilobectomy or lobectomy were included. Exclusion criteria included death, need for revision surgery, occurrence of a different primary cancer within 5 years and incomplete medical records.

Multivariate logistic regression models showed that opioid dosage was not associated with either recurrence (Wald chi-square, 0.4128; p=0.520) or death (Wald chi square, 0.1939; p=0.659). However, when taking cancer stage into account, opioid use was significantly correlated with recurrence (p=0.004) and death (p=0.049).

A 1-unit increase in opioid dosage was correlated with a significant increase in recurrence for cancer stages IA (odds ratio [OR], 1.001; 95 percent CI, 1.001 to 1.001; p=0.004), IB (OR, 1.001; 1.000 to 1.001; p=0.02) and IB (OR, 1.001; 1.001 to 1.002; p=0.0006).

Similar significant increases in the risk of death in cancer stages IA (OR, 1.001; 1.000 to 1.001; p=0.0105), IB (OR, 1.001; 1.000 to 1.001; p=0.0317) and IIB (OR, 1.001; 1.000 to 1.001; p=0.0363) were calculated with a 1-unit increase in opioid dosage.

However, because of the small magnitude of the ORs, it may be concluded that opioid usage does not affect risk of death or recurrence in NSCLC regardless of stage, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.